Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reversal of Milvexian Effects by 4F-PCC and rFVIIa in Healthy Subjects
NCT04543383Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milvexian in thromboembolism, stroke, acute coronary syndrome (ACS) and 1 more, sponsored by Janssen Pharmaceutical. Primary endpoints: Activated Partial Thromboplastin Time at Day 4, Endogenous Thrombin Potential at Day 4 and 3 more. Started Jul 2020; status: completed.
02
Drugs
milvexian
03
Conditions
thromboembolismstrokeacute coronary syndrome (ACS)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04543383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543383.